Education
About Us
Working with TipRanks
Follow Us
Corvus Pharmaceuticals Inc. (CRVS)
:CRVS
CRVS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.30 - $10.00
Previous CloseN/A
Volume202.27K
Average Volume (3M)728.86K
Market Cap
$203.04M
Enterprise Value$314.81M
Total Cash (Recent Filing)$12.52M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.54
Next Earnings
May 01, 2025EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.97
Shares Outstanding68,135,796
10 Day Avg. Volume805,861
30 Day Avg. Volume728,863
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-11.00
P/FCF Ratio0.00
Enterprise Value/Market Cap1.55
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-11.46
Forecast
1Y Price Target
$12.33Price Target Upside313.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Corvus Pharmaceuticals News
PremiumCompany Announcements
Corvus Pharmaceuticals Appoints New Director to Board
PremiumCompany Announcements
Corvus Pharmaceuticals’ Earnings Call: Progress Amid ChallengesPremiumCompany Announcements
Corvus Pharmaceuticals Reports 2024 Financial Results and Clinical Progress
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe planned release of updated results from the company’s Phase 1 study of soquelitinib in patients with moderate to severe atopic dermatitis could be a major catalyst for Corvus.
Financial StabilityCorvus has reported having cash and cash equivalents of $52M, which is believed to be sufficient to fund operations through early 2026.
Market PotentialPositive data in atopic dermatitis could open opportunities for soquelitinib in other immune diseases, potentially increasing the stock value.
Bears Say
Market SentimentThe significant drop in CRVS shares may reflect market disappointment in soquelitinib's efficacy data compared to Dupixent and prior confident management comments.
---
Ownership Overview
34.59% Insiders
4.68% Mutual Funds
43.70% Other Institutional Investors
12.32% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRVS FAQ
What was Corvus Pharmaceuticals Inc.’s price range in the past 12 months?
Corvus Pharmaceuticals Inc. lowest stock price was $1.30 and its highest was $10.00 in the past 12 months.
What is Corvus Pharmaceuticals Inc.’s market cap?
Corvus Pharmaceuticals Inc.’s market cap is $203.04M.
When is Corvus Pharmaceuticals Inc.’s upcoming earnings report date?
Corvus Pharmaceuticals Inc.’s upcoming earnings report date is May 01, 2025 which is in 17 days.
How were Corvus Pharmaceuticals Inc.’s earnings last quarter?
Corvus Pharmaceuticals Inc. released its earnings results on Mar 25, 2025. The company reported -$0.18 earnings per share for the quarter, missing the consensus estimate of -$0.117 by -$0.063.
Is Corvus Pharmaceuticals Inc. overvalued?
According to Wall Street analysts Corvus Pharmaceuticals Inc.’s price is currently Undervalued.
Does Corvus Pharmaceuticals Inc. pay dividends?
Corvus Pharmaceuticals Inc. does not currently pay dividends.
What is Corvus Pharmaceuticals Inc.’s EPS estimate?
Corvus Pharmaceuticals Inc.’s EPS estimate is -0.12.
How many shares outstanding does Corvus Pharmaceuticals Inc. have?
Corvus Pharmaceuticals Inc. has 68,135,796 shares outstanding.
What happened to Corvus Pharmaceuticals Inc.’s price movement after its last earnings report?
Corvus Pharmaceuticals Inc. reported an EPS of -$0.18 in its last earnings report, missing expectations of -$0.117. Following the earnings report the stock price went down -14.758%.
Which hedge fund is a major shareholder of Corvus Pharmaceuticals Inc.?
Currently, no hedge funds are holding shares in CRVS
---
Corvus Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.33 (313.76% Upside)
$12.33 (313.76% Upside)
Blogger Sentiment
Bullish
CRVS Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.3%
Last 30 Days ▼ 4.2%
Last 30 Days ▼ 4.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
91.02%
12-Months-Change
Fundamentals
Return on Equity
-174.85%
Trailing 12-Months
Asset Growth
51.27%
Trailing 12-Months
Company Description
Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.
---
CRVS Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed sentiment with notable progress in clinical trials, increased cash reserves, and strategic advancements offset by increased losses and expenses. While the company's financial health shows challenges, the advancements in drug development and potential future catalysts provide optimism.Read More>---
CRVS Stock 12 Month Forecast
Average Price Target
$12.33
▲(313.76% Upside)
Technical Analysis
Best Analysts Covering CRVS
1 Year
1 Year Success Rate
5/9 ratings generated profit
1 Year Average Return
+79.53%
reiterated a buy rating 21 days ago
Copying Jeff Jones's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +79.53% per trade.
---